Project Grant R01AI192977
- The federal Project Grant award of $3,089,360 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and evaluation of innovative tuberculosis (TB) diagnostic platforms and assays. The 5-year project, awarded to Rutgers, The State University of New Jersey, aims to accelerate promising TB diagnostics through a fast-paced pipeline that includes technology scouting, development...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $238,500 project grant to the University of California, San Diego (UC San Diego) to develop a novel electrochemical lateral flow assay (ELFA) for the point-of-need diagnosis of tuberculosis (TB). The objective is to create a highly sensitive and specific blood or urine test that can accurately distinguish active TB disease from...
- This federal Project Grant award of $743,817 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to delineate T cell receptor (TCR) families associated with protection from progression to pulmonary tuberculosis (TB) disease. The research will use advanced imaging techniques like fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET-CT) to identify TB-exposed household...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,760,584 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the Regents of the University of California, San Francisco (UCSF) for the "RAPID RESEARCH FOR DIAGNOSTICS DEVELOPMENT IN TB NETWORK: EPISODE 2 (R2D2 TB NETWORK II)" project. The goal of this project is to address the critical unmet need for better tuberculosis (TB) diagnostics in high-burden...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), Catalog of Federal Domestic Assistance (CFDA) 93.855 Allergy and Infectious Diseases Research program, aims to inform the development of a simple, highly sensitive and specific, non-sputum-based point-of-care test (POCT) for tuberculosis (TB) diagnosis. The $850,711 award to Albert Einstein College of Medicine, located in Bronx, NY, will support the investigation of a panel of six monoclonal...
- This $854,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to assess post-tuberculosis (TB) lung disease in TB patients with and without HIV coinfection. The project will utilize novel positron emission tomography (PET) imaging techniques, such as 11C-rifampin PET, to longitudinally profile lesional characteristics and antibiotic exposures in animal models...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on integrating point-of-care urine isoniazid testing into routine tuberculosis (TB) care in India. The research aims to facilitate early and accurate identification of TB patients who are at risk of poor outcomes, including death and disease recurrence, due to...
- This Project Grant award of $802,499, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to characterize the genetic factors involved in tuberculosis (TB) susceptibility and their interaction with the immune system. The key objectives are to: 1) generate population-level genetic data on 5,000 case-control samples from diverse South African populations to identify genetic markers associated...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- This $1,173,748.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research on the role of asymptomatic tuberculosis (TB) in disease transmission. The research aims to improve understanding of when individuals become infectious and where transmission is occurring, particularly in community settings outside of household contacts. Key areas of focus include characterizing...
This $743,651 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to validate the use of plasma cell-free RNA (cfRNA) as a biomarker for the diagnosis of tuberculosis (TB) and monitoring of treatment. The grant will support the validation of cfRNA signatures in a large patient cohort of 1,378 adults across five countries, and the comparison of cfRNA diagnostic accuracy against other TB host response readouts. This research seeks to address the need for improved diagnostics, as 40-60% of TB patients globally are not initiated on effective treatment due to limitations of current diagnostic methods. The project will leverage well-characterized patient cohorts, advanced molecular assays, and computational approaches to establish cfRNA as a promising new class of blood-based biomarker with the potential to significantly improve TB diagnosis and monitoring.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $743.7k | 7/30/25 |